Mars B. vanʼt Veer

6.0k total citations · 1 hit paper
59 papers, 3.8k citations indexed

About

Mars B. vanʼt Veer is a scholar working on Hematology, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Mars B. vanʼt Veer has authored 59 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Hematology, 23 papers in Pathology and Forensic Medicine and 14 papers in Oncology. Recurrent topics in Mars B. vanʼt Veer's work include Lymphoma Diagnosis and Treatment (22 papers), Acute Myeloid Leukemia Research (14 papers) and Acute Lymphoblastic Leukemia research (12 papers). Mars B. vanʼt Veer is often cited by papers focused on Lymphoma Diagnosis and Treatment (22 papers), Acute Myeloid Leukemia Research (14 papers) and Acute Lymphoblastic Leukemia research (12 papers). Mars B. vanʼt Veer collaborates with scholars based in Netherlands, United States and Germany. Mars B. vanʼt Veer's co-authors include Flora E. van Leeuwen, Berthe M.P. Aleman, Willem J. Klokman, Alexandra W. van den Belt‐Dusebout, Harry Bartelink, Eero Pukkala, Charles F. Lynch, Eric J. Holowaty, Bengt Glimelius and Lois B. Travis and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and Blood.

In The Last Decade

Mars B. vanʼt Veer

58 papers receiving 3.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Long-Term Cause-Specific Mortality of Patients Treated for Hodgkin’s Disease

2003 504 citations Berthe M.P. Aleman, Willem J. Klokman et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mars B. vanʼt Veer Netherlands	24	1.7k	1.0k	806	685	657	59	3.8k
R. D. T. Jenkin Canada	32	848 0.5×	898 0.9×	1.3k 1.6×	592 0.9×	425 0.6×	57	4.2k
Harald Anderson Sweden	34	970 0.6×	1.3k 1.2×	956 1.2×	499 0.7×	567 0.9×	79	4.1k
Marie‐Cécile Le Deley France	37	1.4k 0.8×	1.3k 1.2×	1.9k 2.4×	523 0.8×	400 0.6×	177	5.0k
Frederick B. Ruymann United States	32	1.3k 0.8×	1.4k 1.3×	2.4k 3.0×	1.0k 1.5×	915 1.4×	78	4.7k
Alexandra W. van den Belt‐Dusebout Netherlands	17	947 0.6×	729 0.7×	734 0.9×	321 0.5×	434 0.7×	27	3.2k
Catherine Sebban France	36	3.3k 2.0×	3.0k 2.9×	649 0.8×	959 1.4×	232 0.4×	92	5.5k
Lillian M. Fuller United States	37	2.9k 1.7×	1.7k 1.6×	1000 1.2×	406 0.6×	177 0.3×	101	4.3k
Willem J. Klokman Netherlands	13	1.2k 0.7×	802 0.8×	802 1.0×	300 0.4×	371 0.6×	14	2.6k
G. Vaughan Hudson United Kingdom	33	3.1k 1.8×	2.0k 1.9×	915 1.1×	377 0.6×	159 0.2×	66	4.0k
Aspasia Stamatoullas France	34	1.7k 1.0×	1.3k 1.3×	289 0.4×	701 1.0×	290 0.4×	126	3.6k

Countries citing papers authored by Mars B. vanʼt Veer

Since Specialization

Citations

This map shows the geographic impact of Mars B. vanʼt Veer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mars B. vanʼt Veer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mars B. vanʼt Veer more than expected).

Fields of papers citing papers by Mars B. vanʼt Veer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mars B. vanʼt Veer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mars B. vanʼt Veer. The network helps show where Mars B. vanʼt Veer may publish in the future.

Co-authorship network of co-authors of Mars B. vanʼt Veer

This figure shows the co-authorship network connecting the top 25 collaborators of Mars B. vanʼt Veer. A scholar is included among the top collaborators of Mars B. vanʼt Veer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mars B. vanʼt Veer. Mars B. vanʼt Veer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Doorduijn, Jeanette K., Josée M. Zijlstra, Pieternella J. Lugtenburg, et al.. (2020). Bortezomib maintenance after R‐CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial. British Journal of Haematology. 190(3). 385–393. 11 indexed citations

Bruin, Marie L. De, Lucille D.A. Dorresteijn, Mars B. vanʼt Veer, et al.. (2009). Increased Risk of Stroke and Transient Ischemic Attack in 5-Year Survivors of Hodgkin Lymphoma. JNCI Journal of the National Cancer Institute. 101(13). 928–937. 159 indexed citations

Heutte, Natacha, Aspasia Stamatoullas‐Bastard, Patrice Carde, et al.. (2009). Survival after Hodgkin lymphoma. Cancer. 115(8). 1680–1691. 57 indexed citations

Travis, Lois B., Deirdre A. Hill, Graça M. Dores, et al.. (2005). Cumulative Absolute Breast Cancer Risk for Young Women Treated for Hodgkin Lymphoma. JNCI Journal of the National Cancer Institute. 97(19). 1428–1437. 280 indexed citations

Travis, Lois B., Deirdre A. Hill, Graça M. Dores, et al.. (2003). Breast Cancer Following Radiotherapy and Chemotherapy Among Young Women With Hodgkin Disease. JAMA. 290(4). 465–465. 457 indexed citations

Levin, Mark‐David, et al.. (2003). Visual scoring versus histogram subtraction of in vivo binding of immunoglobulins against platelets after transfusion. Cytometry Part B Clinical Cytometry. 57B(1). 40–46. 2 indexed citations

Kluin‐Nelemans, Hanneke C., Elisabeth R. van Wering, C. Ellen van der Schoot, et al.. (2001). SIHONSCORE: a scoring system for external quality control of leukaemia/lymphoma immunophenotyping measuring all analytical phases of laboratory performance. British Journal of Haematology. 112(2). 337–343. 7 indexed citations

Kappers‐Klunne, M. C. & Mars B. vanʼt Veer. (2001). Cyclosporin A for the treatment of patients with chronic idiopathic thrombocytopenic purpura refractory to corticosteroids or splenectomy. British Journal of Haematology. 114(1). 121–125. 90 indexed citations

Béné, Marie C., Michel Bernier, Olivier Casasnovas, et al.. (2001). Acute myeloid leukaemia M0: haematological, immunophenotypic and cytogenetic characteristics and their prognostic significance: an analysis in 241 patients. British Journal of Haematology. 113(3). 737–745. 52 indexed citations

10.

Leeuwen, Flora E. van, Willem J. Klokman, Mars B. vanʼt Veer, et al.. (2000). Long-Term Risk of Second Malignancy in Survivors of Hodgkin’s Disease Treated During Adolescence or Young Adulthood. Journal of Clinical Oncology. 18(3). 487–487. 302 indexed citations

11.

Klauw, Melanie M. van der, R Goudsmit, M. Ruud Halie, et al.. (1999). A Population-Based Case-Cohort Study of Drug-Associated Agranulocytosis. Archives of Internal Medicine. 159(4). 369–369. 122 indexed citations

12.

Dekker, A. W., Mars B. vanʼt Veer, W Sizoo, et al.. (1997). Intensive postremission chemotherapy without maintenance therapy in adults with acute lymphoblastic leukemia. Dutch Hemato-Oncology Research Group.. Journal of Clinical Oncology. 15(2). 476–482. 49 indexed citations

13.

Gratama, Jan‐Willem, et al.. (1996). Low-Dose rIL-2-Induced Remission of Disseminated CD30+ Anaplastic Large-Cell Lymphoma Through Reinforcement of Presumed T-Cell-Mediated Tumor Cell Killing, Complicated by Unilateral Drowning of Lymphoma-Infiltrated Lung. Journal of Immunotherapy. 19(2). 162–167. 2 indexed citations

14.

Schouten, H, et al.. (1996). High-dose therapy followed by bone marrow transplantation for relapsed follicular non-hodgkin's lymphoma. Annals of Hematology. 73(6). 273–277. 12 indexed citations

15.

Segeren, Christine M., et al.. (1995). AML-M0: clinical entity or waste basket for immature blastic leukemias? A description of 14 patients. Annals of Hematology. 70(6). 297–300. 12 indexed citations

16.

Lambrechts, A.C., et al.. (1994). Clinical significance of t(14; 18)-positive cells in the circulation of patients with stage III or IV follicular non-Hodgkin's lymphoma during first remission.. Journal of Clinical Oncology. 12(8). 1541–1546. 44 indexed citations

17.

Veer, Mars B. vanʼt. (1992). The diagnosis of acute leukemia with undifferentiated or minimally differentiated blasts. Annals of Hematology. 64(4). 161–165. 26 indexed citations

18.

Veer, Mars B. vanʼt, Hanneke C. Kluin‐Nelemans, C. Ellen van der Schoot, et al.. (1992). Quality assessment of immunological marker analysis and the immunological diagnosis in leukaemia and lymphoma: a multi‐centre study. British Journal of Haematology. 80(4). 458–465. 22 indexed citations

19.

Adriaansen, Henk J, Herbert Hooijkaas, M. C. Kappers‐Klunne, et al.. (1990). Double Marker Analysis for Terminal Deoxynucleotidyl Transferase and Myeloid Antigens in Acute Nonlymphocytic Leukemia Patients and Healthy Subjects. Hämatologie und Bluttransfusion. 33. 41–49. 14 indexed citations

20.

Coebergh, J.W.W., A van der Does-van den Berg, Elisabeth R. van Wering, et al.. (1989). Childhood leukaemia in The Netherlands, 1973–1986: Temporary variation of the incidence of acute lymphocytic leukaemia in young children. British Journal of Cancer. 59(1). 100–105. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact